Short answer
AbbVie Inc (ABBV) filed an 8-K current report with the SEC on July 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Preliminary Q2 2026 acquired IPR&D and milestone expense: $291 million pre-tax.
AbbVie Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary Q2 2026 acquired IPR&D and milestone expense: $291 million pre-tax
- Expense reduces GAAP and adjusted diluted EPS by $0.17
- Q2 2026 adjusted EPS guidance, including expense: $3.57–$3.61
- Full-year 2026 adjusted EPS guidance, including expense: $13.91–$14.11
- Results remain preliminary pending financial statement closing procedures
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 acquired IPR&D and milestones expense of $291 million reduces adjusted diluted EPS guidance by $0.17
- Full-year 2026 adjusted diluted EPS guidance lowered to $13.91–$14.11 from $14.08–$14.28
- Full-year acquired IPR&D and milestones expense now totals $1,035 million
- Guidance excludes additional post-Q2 2026 acquired IPR&D and milestones expenses due to forecasting uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AbbVie Inc 8-K filings
Get the next ABBV 8-K as it lands
Follow ABBV for push alerts, or ask the research agent what this filing means.